Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Michèle Cavo, Joan Bladé, +27

The Lancet

Hematological MalignancyOverall SurvivalMedicineHematologyMyeloid Neoplasia +5

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Nizar J. Bahlis, Meletios Α. Dimopoulos, Darrell White, +15

Leukemia

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma

Alfred L. Garfall, Edward A. Stadtmauer, Wei‐Ting Hwang, +26

JCI Insight

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Philippe Moreau, Cyrille Hulin, Aurore Perrot, +49

The Lancet Oncology

Hematological MalignancyMedicineAutologous Stem-cell TransplantImmunologyHematology +4

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Jesús F. San Miguel, Hervé Avet‐Loiseau, Bruno Paiva, +24

Blood

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts

Maria Krevvata, Barbara C. Silva, John S. Manavalan, +17

Blood

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Michèle Cavo, Jesús F. San Miguel, Saad Z. Usmani, +24

Blood

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Hervé Avet‐Loiseau, Jesús F. San Miguel, Tineke Casneuf, +19

Journal of Clinical Oncology

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

Yaël C. Cohen, Daniel Morillo, Moshe E. Gatt, +16

Journal of Clinical Oncology

ImmunologyImmune RegulationImmunoeditingImmunotherapeuticsImmunotherapy +21

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria, +27

Nature Medicine